ASH: Astellas looks for silver linings in failed Xospata combo trial
Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol ...
Continue Reading →
